Atossa Therapeutics received second positive safety assessment in clinical study of AT-301 Coronavirus nasal spray
On Sept. 17, 2020, Atossa Therapeutics announced a positive interim safety assessment from the second cohort of healthy…
-
-
Roche’s phase III EMPACTA study showed reduced likelihood of ventilation in hospitalised patients with COVID-19 associated pneumonia
On Sept. 17, 2020, Roche announced that the phase III EMPACTA study met its primary endpoint, showing that…
-
NIH funded community engagement research efforts in areas hardest hit by COVID-19
On Sept. 16, 2020, the NIH announced a $12 million award for outreach and engagement efforts in ethnic…
-
Lilly announced proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
On Sept. 16, 2020, Eli Lilly announced proof of concept data from an interim analysis of the BLAZE-1…
-
T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity
On Sept. 16, 2020, a study by researchers at La Jolla Institute for Immunology published in the Cell,…
-
NanoViricides nominated a novel candidate for advancing Into clinical trials for treatment of COVID-19
On Sept. 16, 2020, NanoViricides announced that it had nominated a clinical drug candidate for the treatment of…
-
AIM ImmunoTech announced start of recruitment in clinical trial incorporating Ampligen in treatment of cancer patients with COVID-19
On Sept. 16, 2020, AIM ImmunoTech announced that recruitment had begun in Roswell Park Comprehensive Cancer Center’s Phase…
-
COVID-19 | FDA | Therapeutics
AXIM Biotechnologies filed Emergency Use Authorization with COVID-19 rapid diagnostic test for neutralizing antibodies
On Sept. 16, 2020, AXIM Biotechnologies announced that it had filed an Emergency Use Authorization (EUA) application with…
-
Novavax announced COVID-19 vaccine manufacturing agreement with Serum Institute of India
On Sept. 15, 2020, Novavax announced an amendment to its existing agreement with Serum Institute of India which…
-
Arizona COVID-19 Genomics Union tracked strains of SARS-CoV-2
On Sept. 15, 2020, initial findings reported by the Arizona COVID-19 Genomics Union (ACGU) suggested that following Arizona’s…
-
Laboratory testing of Brilacidin for COVID-19 in combination with remdesivir reduces viral load by nearly 100 percent
On Sept. 15, 2020, Innovation Pharma reported additional data from a U.S. Regional Biocontainment Laboratory (RBL) collected during…
-
New anti-infective drugs had a 14% speed advantage vs other drugs from 2000-2019
On Sept. 15, 2020, the Tufts Center for the Study of Drug Development reported that new anti-infective drugs…
-
USDA research showed higher carbohydrate and balanced fat intake can prevent certain diseases
On Sept. 15, 2020, a team of scientists in the U.S. Department of Agriculture’s (USDA) Agriculture Research Service…
-
NIH awarded contracts worth $228 million to develop innovative digital health technologies for COVID-19
On Sept. 15, 2020, the NIH awarded seven contracts worth a total of $22.8 million to companies and…
-
FDA contracted with global partners to analyze coronavirus samples
On Sept. 15, 2020, the FDA awarded a $5.4 million research contract to the University of Liverpool and…
-
Biotechnology | COVID-19 | Diagnostics | FDA | Infectious Disease | Life Science History | Medical Device
FDA published comparative performance data for COVID-19 molecular diagnostic tests
On Sept. 15, 2020, the FDA published comparative performance data for some authorized COVID-19 molecular diagnostic tests. The…
-
Biotechnology | COVID-19 | Infectious Disease | Influenza | NIH | Vaccine
Vaxess Technologies to develop Coronavirus + Influenza Combo Patch Vaccine in Partnership with Medigen
On Sept. 15, 2020, Vaxess Technologies and Medigen Vaccine Biologics (MBV) announced a partnership to develop a combined…
-
Thermo Fisher Scientific further expanded laboratory plastics production to support COVID-19 testing, therapies and vaccines
On Sept. 15, 2020, Thermo Fisher Scientific announced it was investing more than $140 million to further expand…
-
Soligenix announced publication demonstrating thermostabilization of filovirus vaccine antigens
On Sept. 15, 2020, Soligenix announced publication of nonclinical results characterizing filovirus protein antigens (including for Ebola and…
-
Tonix Pharma enrolled first patient in COV-LOGIC study to assess antibody and T cell responses to SARS-CoV-2
On Sept. 15, 2020,Tonix Pharmaceuticals announced that the first patient was enrolled in the observational COV-LOGIC study (TNX-C001),…
-
OPKO Health initiated clinical trial of RAYALDEE in COVID-19 patients
On Sept. 15, 2020, OPKO Health announce it had initiated a Phase 2 trial with RAYALDEEﾮ as a…
-
BioNTech received ﾀ375M in funding from German Federal Ministry to support COVID-19 vaccine program BNT162
On Sept. 15, 2020, BioNTech announced that had receive a grant of up to 375 million Euro from…
-
Factors inherent to obesity could increase vulnerability to COVID-19
On Sept. 15, 2020, UT Southwestern research suggested conditions related to obesity, including inflammation and leaky gut, leave…
-
UTHealth joined NIH trial to test antibodies and other experimental outpatient treatments for COVID-19 pneumonia
On Sept. 15, 2020, the University of Texas Health Science Center at Houston (UTHealth) announced that a study…
-
Vaxart announced FDA clearance of IND application for oral COVID-19 vaccine
On Sept. 14, 2020, Vaxart announced that the FDA had completed its review of the Companyﾒs Investigational New…
-
Genomic leaders collaborated to create Australia’s first national COVID-19 tracking system
On Sept. 14, 2020, Illumina announced that the Australian public health laboratories will aim to sequence the virus…
-
Humanigen and Lonza announced collaboration to expand manufacturing of Humanigen’s COVID-19 therapeutic Candidate Lenzilumab
On Sept. 14, 2020, Humanigen and Lonza announced a strategic collaboration to expand the manufacturing capacity for lenzilumab…
-
Humanigen announced review of lenzilumab phase 3 study in COVID-19 by Data Safety Monitoring Board
On Sept. 14, 2020, Humanigen announced its Phase 3 registration trial of lenzilumab in patients with COVID-19 was…
-
Biotechnology | COVID-19 | NIH | Therapeutics
Baricitinib in combination with remdesivir reduced time to recovery in hospitalized patients with COVID-19 in ACTT-2 Trial
On Sept. 14, 2020, Eli Lilly and Incyte announced initial data from the Adaptive COVID-19 Treatment Trial (ACTT-2)…
-
Text analysis software track global biothreats, such as COVID-19
On Sept. 14, 2020, at the Pacific Northwest National Laboratory (PNNL) reported that U.S. analysts monitoring global biothreats…
